Literature DB >> 20080410

A retrospective clinical and angiographic study of the coiling outcome of ruptured intracranial aneurysms.

Mostafa Saleh Melake1, Munetaka Yamamoto, Kensaku Yoshida, Hidenori Oishi, Hajime Arai, Mohamed Elwan, Mohamed Okda, Wafik El-Sheikh, Tomokatsu Hori.   

Abstract

Many factors that determine the outcome of endovascular treatment of ruptured intracranial aneurysms are still controversial. We conducted a retrospective study of 203 patients with ruptured aneurysms treated by coiling to assess these factors. The Glasgow Outcome Scale score was used for clinical follow-up and magnetic resonance angiography for angiographic follow-up. Overall outcome and pretreatment variables predicting outcome were thoroughly analyzed. Good clinical grade on presentation was correlated with a better clinical outcome (p<0.001); however, symptomatic vasospasm (15.8% of patients) was correlated with a worse clinical outcome (p<0.001). Six patients (3%) suffered ischemic complications at the time of treatment, hemorrhagic events occurred in five patients (2.5%), permanent morbidity in five patients (2.5%) and overall mortality in 5.4%. In this series, we studied some factors currently debated in the literature and concluded that elderly patients (> or =65 years) with aneurysmal subarachnoid hemorrhage can safely be treated with endovascular therapy with a favorable outcome and that middle cerebral artery aneurysms can be safely embolized with results comparable to other locations. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20080410     DOI: 10.1016/j.jocn.2009.06.025

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  1 in total

1.  Five to ten years follow-up after coiling of 241 patients with acutely ruptured aneurysms. A single centre experience.

Authors:  A Consoli; L Renieri; R Mura; S Nappini; F Ricciardi; G Pecchioli; F Ammannati; S Mangiafico
Journal:  Interv Neuroradiol       Date:  2012-03-16       Impact factor: 1.610

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.